Our top pick for
Progenity Inc is a biotechnology business based in the US. Progenity shares (PROG) are listed on the NASDAQ and all prices are listed in US Dollars. Progenity employs 511 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.96|
|52-week range||$0.72 - $8.20|
|50-day moving average||$1.52|
|200-day moving average||$2.30|
|Wall St. target price||$6.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.28|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-1.33%|
|1 month (2021-09-24)||228.89%|
|3 months (2021-07-26)||15.63%|
|6 months (2021-04-26)||-5.73%|
|1 year (2020-10-23)||-62.58%|
|2 years (2019-10-22)||N/A|
|3 years (2018-10-22)||N/A|
|5 years (2016-10-22)||N/A|
|Revenue TTM||$74.9 million|
|Gross profit TTM||$-19,120,000|
|Return on assets TTM||-86.16%|
|Return on equity TTM||0%|
|Market capitalisation||$392.9 million|
TTM: trailing 12 months
There are currently 10.7 million Progenity shares held short by investors – that's known as Progenity's "short interest". This figure is 21.5% up from 8.8 million last month.
There are a few different ways that this level of interest in shorting Progenity shares can be evaluated.
Progenity's "short interest ratio" (SIR) is the quantity of Progenity shares currently shorted divided by the average quantity of Progenity shares traded daily (recently around 18.2 million). Progenity's SIR currently stands at 0.59. In other words for every 100,000 Progenity shares traded daily on the market, roughly 590 shares are currently held short.
However Progenity's short interest can also be evaluated against the total number of Progenity shares, or, against the total number of tradable Progenity shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Progenity's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Progenity shares in existence, roughly 90 shares are currently held short) or 0.1306% of the tradable shares (for every 100,000 tradable Progenity shares, roughly 131 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Progenity.
Find out more about how you can short Progenity stock.
We're not expecting Progenity to pay a dividend over the next 12 months.
Progenity, Inc. , a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.